| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 13, 2026 | From a start-up biotech firm to a global vaccine giant | |
| Jun 12, 2025 | Немецкая BioNTech приобретает конкурирующую CureVac за $1,25 млрд | В соответствии с согласованной сделкой, которая объединяет двух бывших конкурентов в гонке за разработку вакцины от COVID-19, каждая акция CureVac будет обменена примерно на $5,46 в американских депозитарных акциях (ADS) BioNTech, сообщает ... |
| Jun 12, 2025 | Stocks making the biggest moves midday: Oracle, Boeing, CureVac, Datadog and more | |
| Mar 3, 2025 | METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer | HANGZHOU, China, March 3, 2025 /PRNewswire/ -- METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment of Mark Herbert as Chief Business... |
| Mar 1, 2025 | Circio and Moldova: Two Innovators Shaping the Future of Biotechnology and Digital Transformation | In the rapidly evolving landscape of biotechnology and digital innovation, two distinct narratives emerge from Europe: Circio Holding ASA in Norway and the Moldova Digital Summit. Both represent the pulse of progress, each in their own doma... |
| Mar 1, 2025 | The Future of RNA: Circio's Circular Revolution in Biotechnology | In the world of biotechnology, innovation is the lifeblood. Circio Holding ASA is at the forefront of this revolution. The company is pioneering circular RNA technology, a game-changer in the realm of nucleic acid medicine. This technology ... |
| Feb 26, 2025 | Circio invited to present advantages of circVec circular RNA technology at international industry conferences | Circio invited to present advantages of circVec circular RNA technology at international industry conferences
Wed, Feb 26, 2025 07:00 CET Report this content
Oslo, Norway 26 February 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology co... |
| Jan 15, 2025 | The Race for AI: Innovation and Impending Doom | In the world of artificial intelligence, innovation races ahead like a speeding train. Researchers from AIRI, along with their international partners, have made headlines by reaching the finals of the prestigious Concordia Challenge. This c... |
| Jan 14, 2025 | Нейросети, робототехника и апокалипсис | Как повлияет развитие нейросетей и робототехники на рынок труда? Появится ли в ближайшие годы настоящий сильный ИИ? Если сильный ИИ появится - захочет ли он уничтожить человечество? Не используют ли власти большинства стран нейросети, ИИ и ... |
| Oct 25, 2024 | The Role of Illinois’s Tech Industry in Global Health Initiatives | Share
Tweet
Share
Share
Email
Illinois has emerged as a significant player in the global tech space, particularly in the field of health technology. With a rich tapestry of companies, startups, and research institutions, the state is levera... |
| Jun 2, 2024 | WHO members approve steps to bolster health regulations for pandemics | |
| May 25, 2024 | Efforts to draft pandemic treaty falter as countries disagree on steps | |
| May 10, 2024 | Nations struggle to draft pandemic treaty to avoid mistakes made in Covid | |
| Apr 17, 2024 | Путин: в мире высок риск возникновения новых эпидемий, особенно уязвима Африка | |
| Apr 16, 2024 | Biden govt announces partnership with 50 nations to stifle future pandemics | |
| Feb 10, 2023 | CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares | TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ... |
| Jan 13, 2023 | Here are 5 winners and 4 losers from the healthcare industry's most important event of the year | Westend61/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
The healthcare industry's most influential investor conference was held in person this week. The J.P. Morgan Healthc... |
| Jan 6, 2023 | CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs | Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies
All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA ... |
| Dec 14, 2022 | CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program | TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), to... |
| Nov 21, 2022 | mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next? | This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.”
The unprecedented success of messenger RNA vaccines against the coronavirus is raising hopes that the technology could... |
| Aug 18, 2022 | CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate | Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Milestone demonstrates CureVac's continued execution on comprehensive clinical program of second-generation vaccine candidat... |
| Jul 5, 2022 | CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech | TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today an... |
| Jun 10, 2022 | Amarin fishes for another CFO as downsizing takes hold; CureVac makes a deal, then lines up Novartis exec to lead development | Tom Reilly
→ Mired in flagging sales for Vascepa, the harsh realities of the current climate in biotech have hit Amarin as they slice 40% of the workforce — the majority of those cuts coming from the US commercial team. And t... |
| Apr 22, 2022 | CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022 | TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report ... |
| Apr 12, 2022 | Manufacturing problems trigger another clinical hold for troubled Covid-19 vaccine — latest in a string of roadblocks | Just days after the World Health Organization suspended the use of Covaxin after a manufacturing site failed an inspection, the FDA has followed up with a clinical hold on the Covid-19 vaccine’s US co-developer.
Det... |
| Apr 11, 2022 | CureVac and GSK Enter into Pandemic Preparedness Contract with German Government | - German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
- Five-year contract enables production of up to 80 million vaccine doses at short notice in case o... |
| Apr 11, 2022 | Germany deal with CureVac and GSK primed for 80M mRNA vaccines a year | If there’s another pandemic, the German government is determined not to be caught off-guard when it comes to manufacturing vaccines.
CureVac and GSK have signed a deal to supply Germany with mRNA vaccines for pandemic p... |
| Mar 30, 2022 | CureVac and Glaxo Begin Testing New ‘Second Generation’ Covid-19 Vaccine | CureVac and GlaxoSmithKline said Wednesday that they had dosed the first patient in the first trial of what they call their second-generation messenger RNA vaccine for Covid-19.
The companies said that the development program to test the va... |
| Mar 30, 2022 | CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV | Phase 1 dose-escalation study started at clinical sites in the U.S.
Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases
TÜBINGEN, G... |
| Mar 1, 2022 | CureVac establishes RNA printer-specific company as light at the end of tunnel nears | When CureVac CEO Franz-Werner Haas attended the inaugural mRNA health conference in 2013, there were just 80 people in attendance, largely from Moderna, BioNTech and his own company. Nine years later, there were nearly ... |
| Nov 19, 2021 | CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update | DGAP-News: CureVac / Key word(s): Quarter Results
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
18.11.2021 / 22:10
The issuer is solely responsible for the content of th... |
| Nov 19, 2021 | CureVac N : Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update | Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review
Nature publication of promising pre-clinical results for second-... |
| Nov 19, 2021 | CureVac N : Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update - Form 6-K | CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
· Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVI... |
| Aug 17, 2021 | CureVac Says Second Covid-19 Vaccine Was Better in Preclinical Test | The German biotech CureVac and its U.K.-based partner GlaxoSmithKline said early Monday that a second-generation version of CureVac ‘s Covid-19 vaccine had worked better than the first-generation vaccine in a preclinical test in monkeys.
Hu... |
| Aug 16, 2021 | CureVac N : Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update | DGAP-News: CureVac / Key word(s): Quarter Results/Half Year Results
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
16.08.2021 / 13:10
The issuer is solely responsible for the c... |
| Aug 16, 2021 | CureVac N : Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update | Continuation of corporate transformation into commercial-ready biopharma company
Management team strengthened with appointments of Chief Operating Officer Malte Greune and Chief Development Officer Klaus Edvardsen
First-generation COVID-19 ... |
| Aug 16, 2021 | CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study | DGAP-News: CureVac / Key word(s): Study results/Study
CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
16.08.2021 / 13:00
The issuer is solely res... |
| Aug 16, 2021 | GlaxoSmithKline : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study | For media and investors only
Issued: London UK and Tübingen, Germany / Boston, USA
Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared... |
| Jul 1, 2021 | Covid-19 roundup: CureVac pushes ahead for vaccine authorization despite failing to hit 50% efficacy threshold | All mRNA vaccines are not created equal. And Germany-based CureVac found out the hard way on Wednesday as its pivotal trial showed its vaccine is 48% effective against Covid-19 across all age groups studied.
While regulators... |
| Jun 30, 2021 | CureVac N : Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer® | TÜBINGEN, Germany / BOSTON, USA - June 30, 2021
CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ('mRNA'), today announced ... |
| Jun 30, 2021 | CureVac N : Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R) | DGAP-News: CureVac / Key word(s): Personnel
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
30.06.2021 / 13:00
Th... |
| Jun 17, 2021 | CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effective | CureVac stock plunged 50% in extended trading Wednesday after the German biopharmaceutical company released preliminary efficacy results for its Covid-19 vaccine candidate.
The vaccine candidate demonstrated an interim efficacy of 47% again... |
| Jun 17, 2021 | German biotech CureVac's stock plunges 50% after its Covid-19 vaccine candidate failed clinical trial | Artur Widak/NurPhoto via Getty Images
CureVac lost more than half its value after its Covid-19 vaccine jab showed 47% effectiveness.
Results were based on clinical trials conducted in Latin America and Europe on about 40,000 volunteers.
The... |
| Jun 17, 2021 | German biotech CureVac’s stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial | CureVac lost more than half its value after its COVID-19 vaccine jab showed 47% effectiveness.
Results were based on clinical trials conducted in Latin America and Europe on about 40,000 volunteers.
The company attributed its results to 29 ... |
| Jun 17, 2021 | German biotech CureVac's stock plunges 50% after its COVID-19 vaccine candidate failed a clinical trial | CureVac lost more than half its value after its COVID-19 vaccine jab showed 47% effectiveness.
Results were based on clinical trials conducted in Latin America and Europe on about 40,000 volunteers.
The company attributed its results to 29 ... |
| May 26, 2021 | CUREVAC N.V.
CureVac N : Announces Financial Results for the First Quarter of 2021 and Business Updates | DGAP-News: CureVac / Key word(s): Quarter Results
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
26.05.2021 / 13:00
The issuer is solely responsible for the content of this announcement.
CureVac Annou... |
| May 13, 2021 | CUREVAC N.V.
CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study | DGAP-News: CureVac / Key word(s): Research Update/Study results
CureVac : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
13.05.2021 / 13:30
The issuer is so... |
| May 13, 2021 | CUREVAC N.V.
CureVac N : Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study | Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK
CV2CoV mRNA shows high levels of antigen production in rat model
Fast onset of strong neutralizing antibody titers after first vaccinat... |
| Apr 15, 2021 | CUREVAC N.V.
PRESS RELEASE: CureVac Announces Financial -3- | was partially offset by other operating income driven by higher cost reimbursements received from the Coalition for Epidemic Preparedness Innovations (CEPI) and the German Federal Ministry of Education and Research (BMBF). For the twelve mo... |
| Apr 15, 2021 | CureVac N : Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 | DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
15.04.2021 / 13:30
The issuer is solely responsible for the content of th... |
| Apr 15, 2021 | CUREVAC N.V.
CureVac N : Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 | DGAP-News: CureVac / Key word(s): Quarter Results/Annual Results
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
15.04.2021 / 13:30
The issuer is solely responsible for the content of th... |
| Apr 15, 2021 | CureVac N : Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020 | COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission
Pivotal Phase 2b/3 in Europe and Latin America fully recruit... |
| Mar 23, 2021 | Covid-19 roundup: US expects 'nice increase' in J&J vaccine supply — report; CureVac amends trial protocols for variant efficacy | Despite a slow-paced launch of Johnson & Johnson’s vaccine in the US, the pharma should come close to its 20 million-dose target by the end of the month, White House Covid-19 adviser Andy Slavitt told reporters on Monday, per... |
| Mar 4, 2021 | Novartis pairs up with CureVac to help drive Covid-19 shot production but may miss the show in the US, EU | With the pandemic potentially entering its later stages, major drugmakers like Merck have jumped in to aid in the gargantuan task of manufacturing other companies’ vaccines. Now, after a relatively quiet year, No... |
| Feb 5, 2021 | Covid-19 roundup: UK and CureVac join forces to fight emerging variants; Sanofi and GlaxoSmithKline post snapshot of PhI/II vaccine data | The UK’s Vaccines Taskforce will work with CureVac to track new variants and generate vaccine candidates against them, according to a statement. As part of the deal, the UK will get an initial supply of 50 million doses of t... |
| Dec 4, 2020 | GSK vet Antony Blanc signs on to become CureVac's CBO and CCO; Chris Cabell out, Paul Streck in as Arena Pharmaceuticals CMO | Antony Blanc
→ Enthused about the Phase I data for their Covid-19 mRNA vaccine and believing they’ve cracked the cold-storage code in delivering them, CureVac has brought Antony Blanc into the fray as CBO and chief commercial ... |
| Nov 30, 2020 | PRESS RELEASE : CureVac : CureVac Announces -2- | to moderate fever, fatigue, chills and headache. Following a first data presentation at the American Society of Clinical Oncology (ASCO) in April 2020, the data presented at SITC (Cut-off was October 5, 2020) featured 29 patients treated wi... |
| Nov 30, 2020 | CureVac : CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020 | DGAP-News: CureVac / Key word(s): 9 Month figures/Research Update
CureVac : CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020
30.11.2020 / 13:20
The issuer is solely responsible for... |
| Nov 23, 2020 | Drugmakers behind 3 coronavirus vaccines say they work. Here's everything we know about the race for a vaccine and when you might be able to get a shot. | A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washing... |
| Oct 23, 2020 | Covid-19 roundup: An mRNA player gets a boost out of the latest round of animal data; PhaseBio pulls the plug on treatment trial | The big tell for CureVac $CVAC is coming up with a looming early-stage readout on their mRNA Covid-19 vaccine in the clinic. But for now they’ll make do with an upbeat assessment on the preclinical animal data they used to ... |
| Sep 2, 2020 | Elon Musk Gets German Minister's Full Support in Trip to Berlin Gigafactory Despite Anti-Tesla Protests | Isaiah Alonzo, Tech Times 02 September 2020, 11:09 pm
Tesla and SpaceX CEO, Elon Musk already travelled to Germany and met with the German politicians to discuss his plans with the company's projects in car production, vaccine, and Gigafact... |
| Aug 20, 2020 | Bill Gates-backed CureVac jumps 18% on report it's in advanced talks with the EU for 225 million doses of its potential COVID-19 vaccine | Advertisement
CureVac, a German biotech backed by Bill Gates, said Thursday it is in talks with the EU to supply 225 million doses of its potential coronavirus vaccine.
Shares of CureVac jumped more than 18% in premarket trading on Thursday... |
| Aug 14, 2020 | GLAXOSMITHKLINE PLC
Coronavirus vaccine developer CureVac raises $213 million in IPO | The German biotechnology firm sold 13.33 million shares at $16 apiece, the top end of its indicated price range, the source said, requesting anonymity ahead of an initial announcement. The IPO gives CureVac a valuation of about $2.8 billion... |
| Aug 14, 2020 | Coronavirus vaccine developer CureVac raises US$213 million in IPO: source | NEW YORK: CureVac BV raised US$213 million in its initial public offering on Thursday, a person familiar with the matter said, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the nove... |
| Aug 10, 2020 | German Covid-19 vaccine developer CureVac to raise up to $213 mn in US IPO | (Reuters) - German biotech CureVac B.V., which is in early stages of testing its coronavirus vaccine, said on Monday it expects to raise up to $213 million in its U.S. initial public offering (IPO). CureVac said it expects its offering of 1... |
| Jul 21, 2020 | CureVac closes $640M investment amid COVID-19 vaccine race | CureVac has closed a $640 million private financing round. The raising of the round, which is larger than all CureVac’s previously disclosed financings combined, comes as the biotech races to bring an mRNA COVID-19 vaccine to market.
Sponso... |
| Jul 21, 2020 | CureVac closes $640M investment amid COVID-19 vaccine race | CureVac has closed a $640 million private financing round. The raising of the round, which is larger than all CureVac’s previously disclosed financings combined, comes as the biotech races to bring an mRNA COVID-19 vaccine to market.
German... |
| Jul 21, 2020 | CureVac AG: CureVac Raises a Total of USD 640 Million in Private Financing Round | DGAP-Media / 21.07.2020 / 10:45
CureVac Raises a Total of USD 640 Million in Private Financing Round
- Financing Round includes previously announced investments from German Federal Government and GSK for an amount of USD 514 million
- Addit... |
| Apr 16, 2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| Apr 9, 2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| Apr 6, 2020 | Vaccine platform technologies to combat emerging infectious diseases | Vaccine platform technologies to combat emerging infectious diseases
06-04-2020
Encouraging progress is being made towards vaccine development against Covid-19. It is essential that we continue to incentivise and fund research into and deve... |
| Mar 17, 2020 | CureVac denies reports that Trump admin sought to acquire Covid-19 vaccine rights | The Washington Post reported later Sunday that German officials would discuss the report in crisis meetings Monday, quoting Interior Minister Horst Seehofer as saying that he had heard from several members of the government that the Trump a... |
| Mar 17, 2020 | Everything you need to know about CureVac, the German drugmaker working on a coronavirus vaccine | (Photo by John Moore/Getty Images)
To respond to the coronavirus pandemic, drug companies have begun researching potential treatments and vaccines.
One of those vaccine developers, a privately held Germany biotech company called CureVac, ho... |
| Mar 16, 2020 | CureVac Rejects Rumors of US Acquisition | CureVac AG, a Tübingen, Germany-based clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed it is making internal efforts focused on the development of a coronavirus vaccine with the g... |
| Mar 12, 2020 | CureVac founder back at the helm; Merck extends immunomodulatory drug discovery program with Sutro | → Daniel Menichella, the CEO of CureVac and the face of its recent endeavors to develop an mRNA vaccine against Covid-19, is stepping down. Founder Ingmar Hoerr is back in charge; the transition happens just days after Meni... |
| Mar 11, 2020 | The German tech unicorns! 10 most valuable new-age startups you should know about in 2020 | Germany is one of the startup capitals in Europe that is home to numerous successful tech companies. The country has a strong foundation for startups with many entrepreneurs and expats. And, the hype around Germany’s tech startup scene is t... |
| Jan 31, 2020 | CureVac jumps into coronavirus vaccine race; EMA backs raft of drugs, including Novo Nordisk, Esperion compounds | → You can add CureVac to the list of new players to jump into the latest effort to contain a pandemic. The mRNA company has joined the global crew already on board with the public-private Coalition for Epidemic Preparedn... |
| Jan 4, 2018 | Biotech investapalooza continues with more venture rounds for startups; OvaScience cuts half of its workforce (again) | Editor’s note: We here at Endpoints News pride ourselves on providing some comprehensive accounts of all the venture cash flowing into biotech companies, but this week that’s become more than a challenge. In just a matter ... |
| May 5, 2017 | Merck vet Robert Plenge moves to Celgene, Gritstone recruits a Genentech star and more | → ImCheck not only has a recent €20 million Series A under its belt, the biotech also named Pierre d’Epenoux as it Chief Executive Officer. D’Epenoux’s previous gigs include head of strategy and business development a... |
| May 2, 2017 | CureVac names a US subsidiary CEO to advance mRNA work; Sunesis shares slide after regulators nix drug app | → Germany’s CureVac has named a US CEO to help advance its work on mRNA. And not surprisingly he’ll be based in the Boston/Cambridge hub, where rival Moderna has been attracting attention — of all varieties. “As CEO of Cure... |
| Jan 12, 2017 | CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns | Ingmar Hoerr
CureVac’s leading mRNA program CV9104, a prostate cancer vaccine, has failed a critical Phase IIb study. And that stinging setback for the most advanced clinical study in the field will raise fresh questions ab... |
| Nov 11, 2016 | CureVac Secures $29.5m in Financing | CureVac AG, a Tubingen, Germany-based developer of drugs that are based on the molecule Messenger RNA (mRNA), secured a total of $29.5m in financing.
Backers included Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierär... |
| Nov 10, 2016 | Term Sheet — Thursday, November 10 | ET CETERA
Hello from Portugal, where Web Summit is underway. Many of the attendees were bleary-eyed yesterday, having stayed up until 4 a.m. watching the U.S. election results on Tuesday. At the conference, the word “Trump” seems to pepper ... |
| Nov 8, 2016 | CureVac grabs a $29.5M round to fuel its mRNA development efforts | Ingmar Hoerr, CureVac CEO
CureVac, the German mRNA biotech, has added a couple of new investors to the mix who are chipping $29.5 million into the operation as it nears a critical juncture on the R&D side of the busin... |
| Nov 8, 2016 | CureVac bags $30M for mRNA R&D, upping total to $360M | CureVac has raised another $29.5 million (€26.7 million) to fund the advance of its mRNA portfolio. The fresh funding comes one year after CureVac tapped The Bill & Melinda Gates Foundation and others for $110 million.
Tübingen, Germany... |
| Nov 3, 2015 | CureVac Raises $110M in Funding | CureVac, a Tubingen, Germany-based clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, raised about $110 million (€100m) in funding.
The round, which added to the approximately $220m raised since founding... |
| Nov 3, 2015 | Daily funding roundup - November 3, 2015 | CureVac raised $110M; Turo landed $47M; Iboss secured $35M
Say goodbye to peer-to-peer car rental service RelayRides, and hello to Turo! The company announced on Tuesday that is has rebranded itself with the new name, and a new vision, one ... |
| Mar 5, 2015 | Gates Foundation gets behind mRNA vaccinework – contributes $52M to CureVac in its biggest biotech deal yet | The technology is meant to be low cost and shelf-stable – it doesn’t react easily to changes in heat or cold,
“If we can teach the body to create its own natural defenses, we can revolutionize the way we treat and prevent diseases,” said Bi... |
| Jan 14, 2014 | With $20M and 15 preclinical candidates, Moderna launches spinoff for mRNA-based cancer drugs | Moderna’s approach employs messenger RNA, which acts as a blueprint for protein production in cell cytoplasm, to enable the body to make its own healing proteins. Last year, AstraZeneca paid $240 million up front for access to 40 drug candi... |
| Sep 18, 2012 | CureVac Secures EUR80 Million in Series D |
TUBINGEN, GERMANY, Clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the completion of an EUR80 million financing round.
>> Click here for more funding data on ... |
| Sep 18, 2012 | CureVac Closes €80M Financing Round | In one of the largest rounds in Europe, CureVac GmbH, a Tübingen, Germany-based clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, has completed an €80m financing round with dievini Hopp... |
| May 11, 2010 | CureVac GmbH Closes €27.6 Financing Round | CureVac GmbH, a Tübingen, Germany-based developer of therapeutic vaccines, closed a €27.6m (approximately US$ 35.25m) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.
The proceeds will enable furth... |
| CureVac sues BioNTech, claiming Covid-19 vaccine infringes key mRNA patents | A Covid-19 vaccine based on the messenger RNA technology of CureVac has yet to successfully emerge from clinical trials, lagging well behind the mRNA shot from rival BioNTech that has landed authorizations and approvals across the world. Bu... |
| With $20M and 15 preclinical candidates, Moderna launches spinoff for mRNA-based cancer drugs | With a $110 million financing round and big-time deals with AstraZeneca and Alexion Pharmaceuticals in the bag, biotech company Moderna Therapeutics‘ next big move is to spin its pipeline of cancer drug candidates into a new, separate ventu... |
| GSK was the world's largest vaccine business but failed to make a COVID-19 shot. A new exec lays out his plans to lead the pharma giant back to the top. | Phil Dormitzer, GSK's global head of vaccines R&D. GSK This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
GSK, once the world's largest vaccine business, stumbled when it came... |
| CureVac denies reports that Trump admin sought to acquire Covid-19 vaccine rights | News reports emerged over the weekend that the Trump administration attempted to poach scientists working for a German biotech firm in order to obtain exclusive rights to a potential vaccine against the Covid-19 virus. However, the company ... |
| Beyond COVID-19 vaccines, mRNA's pioneers have big plans for using the technology against a range of diseases | Employees in special suits test procedures for manufacturing the messenger RNA (mRNA) COVID-19 vaccine from Pfizer-BioNTech, in Marburg, Germany. Abdulhamid Hosbas/Anadolu Agency via Getty Images
Redeem now
BI Graphics
Drugmakers big and sm... |
| Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and more | Check out the companies making the biggest moves midday:
Virgin Orbit — The satellite launch service company fell 13.99% a day after it confirmed its first launch out of the United Kingdom Monday failed to reach orbit. The mission was Virgi... |
| Gates Foundation gets behind mRNA vaccinework – contributes $52M to CureVac in its biggest biotech deal yet | RNA drug discovery just got a huge vote of confidence from the Bill and Melinda Gates Foundation.
One of the biggest priorities of The Bill & Melinda Gates Foundation is vaccine work – it’s pledged to direct billions into biotechs and r... |
